Moomoo report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Why BYAH Stock dropped -13.12% Today — RQD Quant Desk Flash
Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BYAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Park Ha Biological Technology Co. Ltd. (Class A) (NASDAQ: BYAH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.92 (-13.12% 1D, market cap $7.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1011 tracked Consumer Discretionary issuers, BYAH ranks #695 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BYAH compare to BNKK and CABR in the Consumer Discretionary sector?
▼
Within the Consumer Discretionary sector (Package Goods/Cosmetics), BYAH carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 94.4%, and ROIC of —. By comparison, BNKK (Bonk Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.6M) and CABR (Caring Brands Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BYAH?
▼
Per BYAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001986247), Park Ha Biological Technology Co. Ltd. (Class A) generated $2.5M in revenue (+6.0% YoY), -$24.4M in net income, and $85.9K in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 3.4% FCF Margin ($85.9K FCF) & 94.4% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a BYAH Turnaround Squeeze
While BYAH currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Discretionary with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.46) and Max Pain ($2.02) forces dealer call-delta covering toward $165.90.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why BYAH Stock dropped -13.12% Today — RQD Quant Desk Flash
Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) dropped -13.12% to $1.92, trading at 2% of its 52-week range ($1.9 – $158). Stretched risk/reward at current multiples (94% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.9 – $158) with RSI-14 at 43.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.92 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 94.4% gross margin and $85852 annual free cash flow.
TradingView report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYAH)
- ✓Walkthrough of BYAH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
BYAH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BYAH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BYAH. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYAH)
1. Head-to-Head Consumer Discretionary Peer Comparison (BYAH vs. BNKK, CABR, YCBD, UG)
Industry: Package Goods/Cosmetics (23 Tracked Issuers)Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) ranks #695 by composite RQD confidence (43/100, grade D-) and #943 by equity capitalization ($7.6M). Within this direct 5-issuer industry benchmark cohort, UG leads on earnings valuation at 14.5x trailing P/E, while UG leads on capital efficiency and profitability with 17.8% ROIC and — gross margin. UG currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with BYAH at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BYAH
ACTIVE
Park Ha Biological Technology Co. Ltd. (Class A) | D- | 43/100 | — | 94.4% | — | -13.12% | $7.6M | Benchmark Subject |
| BNKK Bonk Inc. | E | 32/100 | — | 58.5% | -35.0% | -1.85% | $8.6M | /bnkk-vs-byah → |
| CABR Caring Brands Inc. | D- | 40/100 | — | 55.6% | -35.0% | -7.96% | $11.8M | /cabr-vs-byah → |
| YCBD cbdMD Inc. | D- | 36/100 | — | 62.4% | -30.4% | +3.66% | $4.3M | /ycbd-vs-byah → |
| UG United-Guardian Inc. | B- | 71/100 | 14.5x | — | 17.8% | +2.55% | $32.5M | /ug-vs-byah → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0001986247In its most recent audited fiscal period (FY2025, filed 2025-10-31), Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) reported GAAP revenue of $2.5M (+6.0% vs. FY2024 revenue of $2.4M , and +2.7% cumulative change since FY2023) , GAAP net income of -$24.4M, operating cash flow of $85.9K, and free cash flow of $85.9K (-91.1% YoY). On the balance sheet, BYAH closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-10-31 | $2.5M | -$24.4M | $85.9K | $85.9K | $6.0M | — |
| FY2024 (FY) | 2024-10-31 | $2.4M | $478.6K | $960.5K | $960.5K | — | — |
| FY2023 (FY) | 2023-10-31 | $2.5M | $852.0K | $126.5K | $126.5K | — | — |
3. BYAH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BYAH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Park Ha Biological Technology Co. Ltd. (Class A) (NASDAQ: BYAH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.92 (-13.12% 1D, market cap $7.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1011 tracked Consumer Discretionary issuers, BYAH ranks #695 in composite RQD confidence.
How does BYAH compare to BNKK and CABR in the Consumer Discretionary sector?
Within the Consumer Discretionary sector (Package Goods/Cosmetics), BYAH carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 94.4%, and ROIC of —. By comparison, BNKK (Bonk Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $8.6M) and CABR (Caring Brands Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BYAH?
Per BYAH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001986247), Park Ha Biological Technology Co. Ltd. (Class A) generated $2.5M in revenue (+6.0% YoY), -$24.4M in net income, and $85.9K in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BYAH trading relative to its 50-day, 200-day, and 52-week technical levels?
BYAH last traded at $1.92 (-13.12% on volume of 35,620 shares), positioning the stock -21.95% below its 50-day simple moving average ($2.46) and -81.25% below its 200-day simple moving average ($10.24). Across its 52-week range of $1.90 to $158.00, BYAH sits at the 0.0% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.68 to $2.16).
BYAH — Park Ha Biological Technology Co. Ltd. (Class A): What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
BYAH scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:
- Fundamental Cash Engine: 14 / 20. ROIC is 0% and FCF yield is 1.09%. FY 2025 net income was -$24.4M against revenue of $2.5M, while FCF was $0.1M. Modest free cash flow relative to a deeply negative earnings line is the central tension in this pillar.
- Whale / 13F Flow: 5 / 20. this pillar reflects institutional accumulation and options positioning. It is the weakest pillar relative to its weight, signaling limited institutional sponsorship in the source data.
- Insider Conviction: 7 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and Congressional flow does not offer meaningful conviction support.
- Macro Regime Fit: 8 / 20. beta is 1.0 and the score reflects sector sensitivity. A beta of 1.0 means the stock moves in line with the broader market rather than offering defensive or amplified exposure.
- Forensic Balance Sheet: 11 / 20. Altman Z is 2.5, Piotroski F is 5/9, and Debt/Equity is 0.5. This is the strongest pillar, though it still reflects only middling financial health.
For a prospective investor evaluating the stock today, the rating points to a weak operating picture: negative operating and net margins, zero ROIC, and a thin free-cash-flow yield. The most constructive element is the balance-sheet pillar; the most concerning is the absence of institutional and insider conviction.
2. Business Model, Unit Margins & SEC Financial Trajectory
. Ltd. (Class A) is a NASDAQ-listed issuer in the Consumer Discretionary sector and the Package Goods/Cosmetics industry. The profile identifies its market capitalization as $0.0B. Per the market data, gross margin is 94.4%, with operating margin at -60%.
Revenue was broadly stable across the three reported periods, while operating and net income swung from positive in FY 2023 and FY 2024 to substantially negative in FY 2025. Per the market data, operating and net margins are both -60%, and ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.5. The forensic pillar score of 11 / 20 reflects this middling balance-sheet posture.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Balance-sheet forensics score the strongest pillar at 11 / 20, with an Altman Z of 2.5 and a Debt/Equity of 0.5. With Fundamental Cash Engine at 14/20 (ROIC —, FCF yield 1.09%) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.90 – $158.00 52-week range.
- 🐻 Primary Bear Case: Net income swung to -$24.4M in FY 2025 from positive results in FY 2023 and FY 2024, with ROIC at 0% and no institutional or insider conviction support. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. The source data therefore does not establish supplier concentration, customer dependency, or cross-sector correlation for BYAH. A prospective investor should note that the absence of mapped links means second-order effects cannot be evaluated from these sources. The only sector-level data point is the classification itself: Consumer Discretionary / Package Goods/Cosmetics.
- Key Question #1: What drove the swing from positive net income of $0.9M (FY 2023) and $0.5M (FY 2024) to a net loss of -$24.4M in FY 2025?
- Key Question #2: Why is the 52-week range $1.9 to $158, and what events account for that magnitude of price movement?
- Key Question #3: What are the company's specific products, customers, and revenue drivers within Package Goods/Cosmetics?
BYAH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) • Click "Debate This Headline" to argue it in the Roar Pit below
Moomoo report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) market action, institutional positioning, and fundamental catalysts.
BYAH Bull vs. Bear Conversation Board — What's Your Call at $1.92?
Balance-sheet forensics score the strongest pillar at 11 / 20, with an Altman Z of 2.5 and a Debt/Equity of 0.5.
Long BYAH at $2.21 targeting $2.65. Balance-sheet forensics score the strongest pillar at 11 / 20, with an Altman Z of 2.5 and a Debt/Equity of 0.5.. Institutional whale score is 3/20 and the risk/reward vs. the $1.90 52-week low is skewed heavily in favor of bulls.
@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $2.21 is dangerous when funds are rotating into Consumer Discretionary.
Net income swung to -$24.4M in FY 2025 from positive results in FY 2023 and FY 2024, with ROIC at 0% and no institutional or insider co
I respect the product at Park Ha Biological Technology Co. Ltd. (Class A), but the stock at $2.21 is a different story. Net income swung to -$24.4M in FY 2025 from positive results in FY 2023 and FY 2024, with ROIC at 0% and no institutional or insider conviction support.. FCF yield is 1.09% and RQD sits at 43/100 (D-) — why pay up here when you can wait for next quarter's numbers?